Life Science News

Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services. As …

Cellular Biomedicine Group (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a Patent License Agreement with the National Cancer Institute (“NCI”), an institute of the National Institutes of Health, within the Department of Health and Human Services.

As quoted in the press release:

Pursuant to the License Agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.

“We are extremely pleased to finalize this License Agreement as this next generation TIL technology will fortify our clinical development pipelines for solid tumors.  It is a significant extension of our CAR/TCR-T pipelines against solid tumors in the immuno-oncology platform,” stated Tony (Bizuo) Liu, Chief Executive Officer of CBMG. “The medical oncology community is very aware of the innovative work using T cell-based immunotherapy and autologous TIL transfer for the treatment of various cancers. We look forward to continuing to advance this field.”

Click here to read the full press release.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×